Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria De Santis

Showing results (161-170 of 278) with videos related to

Pageof 28
Sort By:
Life Science Alliance|February 16, 2022
mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patientsElena Azzolini, Chiara Pozzi, Luca Germagnoli, et al.
American Journal of Preventive Cardiology|January 1, 2026
The risk of cardiovascular death in systemic immune-mediated diseases: A systematic review and meta-analysisStefano Figliozzi, Thanakorn Rojanathagoon, Spyridoula Karogianni, et al.
ACR Open Rheumatology|November 2, 2023
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic SurveyGerlando Natalello, Silvia Laura Bosello, Corrado Campochiaro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987Joaquim Bellmunt, Hans von der Maase, Graham M Mead, et al.
Autoimmunity Reviews|November 3, 2015
Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 yearsCarlo Selmi, Angela Ceribelli, Elena Generali, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)Margitta Retz, Jens Bedke, Martin Bögemann, et al.
Rheumatology (Oxford, England)|January 29, 2020
Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysisGiacomo De Luca, Corrado Campochiaro, Maria De Santis, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 studyAndrea Necchi, Michiel S Van der Heijden, Dmytro Trukhin, et al.
European Urology|September 5, 2016
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate CancerPhilip Cornford, Joaquim Bellmunt, Michel Bolla, et al.
European Urology|July 5, 2016
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder CancerJ Alfred Witjes, Thierry Lebret, Eva M Compérat, et al.
Pageof 28

Showing results (161-170 of 278) with videos related to

Sort By:
Pageof 28
Life Science Alliance|February 16, 2022
mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patientsElena Azzolini, Chiara Pozzi, Luca Germagnoli, et al.
American Journal of Preventive Cardiology|January 1, 2026
The risk of cardiovascular death in systemic immune-mediated diseases: A systematic review and meta-analysisStefano Figliozzi, Thanakorn Rojanathagoon, Spyridoula Karogianni, et al.
ACR Open Rheumatology|November 2, 2023
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic SurveyGerlando Natalello, Silvia Laura Bosello, Corrado Campochiaro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987Joaquim Bellmunt, Hans von der Maase, Graham M Mead, et al.
Autoimmunity Reviews|November 3, 2015
Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 yearsCarlo Selmi, Angela Ceribelli, Elena Generali, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)Margitta Retz, Jens Bedke, Martin Bögemann, et al.
Rheumatology (Oxford, England)|January 29, 2020
Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysisGiacomo De Luca, Corrado Campochiaro, Maria De Santis, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 studyAndrea Necchi, Michiel S Van der Heijden, Dmytro Trukhin, et al.
European Urology|September 5, 2016
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate CancerPhilip Cornford, Joaquim Bellmunt, Michel Bolla, et al.
European Urology|July 5, 2016
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder CancerJ Alfred Witjes, Thierry Lebret, Eva M Compérat, et al.
Pageof 28